BioSpace News Archive

Generex strategy offers ethical and safe solution to rapid vaccine development with Ii-Key-SARS-CoV-2 peptide vaccine SARS-CoV-2 mechanism of infection still largely unknown COVID-19 disease progression remains largely undefined Risk factors for hospitalization include age, cardiovascular disease, hypertension, obesity, and other unknown health and genetic risks Risky strategy of viral challenge studies unnecessarily puts people’s lives in danger MIRAMAR, Fla., April 27, 2020 (GLOBE NEW

Selux Diagnostics, Inc., which is leading a new era in personalized medicine to treat superbug infections and combat antibiotic resistance, today announced that it has been awarded an additional $9.6 million from the Biomedical Advanced Research and Development Authority (BARDA)

Bracco Imaging, a leading global company in the diagnostic imaging business, announced a new initiative called BRACCO CARES.

Carmell to begin enrolling in pivotal clinical program for first-of-its-kind Plasma-based Bioactive Material product used in long-bone fractures as an adjunctive treatment PITTSBURGH--( BUSINESS WIRE )-- Carmell Therapeutics , a pioneer in the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs) to accelerate bone and soft tissue healing, announced that the U.S. Food and Drug Administration (FDA) last week has g

Anika Therapeutics, Inc. today announced that Cheryl R. Blanchard, Ph.D., has been named President and Chief Executive Officer,

The medical device industry was the first to bear the brunt of the COVID-19 epidemic at the end of 2019, and China’s high-end medical device reserves, production and R&D capabilities were well illustrated.

Dr. Reddy’s Laboratories Ltd. announced the launch of Fenofibrate Tablets USP, a therapeutic equivalent generic version of Tricor® Tablets, approved by the U.S. Food and Drug Administration.

Shanghai Green Valley Pharmaceuticals, China received the formal decision letter from the US Food and Drug Administration on the Investigational New Drug application for the GV-971 international multi-center Phase III clinical study.

CARsgen Therapeutics Co., Ltd. announced the European Medicines Agency Committee for Orphan Medicinal Products adopted a positive opinion on CARsgen’s application for orphan designation of its investigational CT053 CAR T-cell therapy, fully human anti-BCMA autologous chimeric antigen receptor T cells for the treatment of multiple myeloma.

COM701 was well-tolerated with no dose-limiting toxicities observed as a monotherapy and in combination with Opdivo® (nivolumab)